Merck & Co., Inc: Candidiasis trials

The registry lists 11 Candidiasis studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 7Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisCompletedNCT03667690Phase 3Results posted
• A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)CompletedNCT01165320Phase 2Results posted
• Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)TerminatedNCT01045798Phase 2Results posted
• Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)CompletedNCT00330395Phase 2
• Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)CompletedNCT00083343Phase 2
• Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)CompletedNCT00082524Phase 2
• PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)CompletedNCT00034671Phase 2
• Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)CompletedNCT00034658Phase 3
• Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)CompletedNCT00034632Phase 3
• A Study of the Side Effects of L-743,872 in Men With Candidal EsophagitisCompletedNCT00005921Not applicable
• A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive PatientsCompletedNCT00002399Phase 2